Carna Biosciences, Inc. (TYO:4572)
Japan · Delayed Price · Currency is JPY 348.00
-2.00 (-0.57%)
Oct 26, 2026, 3:30 PM JST
Carna Biosciences Financials Overview
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 729 | 579 | 636 | 1,625 | 1,386 | 2,017 |
Revenue Growth | 27.45% | -8.96% | -60.86% | 17.24% | -31.28% | 78.02% |
Gross Profit Gross Profit Growth | 506 | 388 | 465 | 1,450 | 1,215 | 1,882 |
Operating Income Operating Income Growth | -1,977 | -2,075 | -2,076 | -1,117 | -1,270 | -531 |
Net Income Net Income Growth | -2,154 | -2,171 | -2,178 | -1,152 | -1,349 | -534 |
Earnings Per Share EPS Growth | -111.33 | -113.60 | -121.61 | -68.57 | -99.06 | -42.06 |
EPS Growth | - | - | - | - | - | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Europe Europe Growth | 84.67 | 47.71 | 61.29 | 112.95 | 72.02 | 80.97 |
United States of America United States of America Growth | 261.13 | 259.61 | 276.86 | - | - | - |
Others Others Growth | 58.77 | 5.99 | 6.8 | 26.33 | 37.88 | 17.89 |
Japan Japan Growth | 227.99 | 169.19 | 198.82 | 223.31 | 218.75 | 205.06 |
China China Growth | - | 96.55 | 92.47 | 128.72 | 202.92 | 71.77 |
Total Total Growth | 729.11 | 579.06 | 636.23 | 1,626 | 1,387 | 2,018 |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 1,100 | 516 | 2,108 | 2,889 | 3,379 | 3,817 |
Total Debt Total Debt Growth | 1,984 | 713 | 59 | 182 | 299 | 539 |
Net Cash (Debt) Net Cash Growth | -884 | -197 | 2,049 | 2,707 | 3,080 | 3,278 |
Net Cash Growth | - | - | -24.31% | -12.11% | -6.04% | -15.32% |
Net Cash Per Share Net Cash Per Share Growth | -45.69 | -10.31 | 114.41 | 161.13 | 226.18 | 258.20 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -2,079 | -2,159 | -1,374 | -1,677 | -708 | -1,536 |
Capital Expenditures CapEx Growth | -13 | -9 | -13 | -11 | -126 | -41 |
Free Cash Flow Free Cash Flow Growth | -2,092 | -2,168 | -1,387 | -1,688 | -834 | -1,577 |
Free Cash Flow Growth | - | - | - | - | - | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 69.41% | 67.01% | 73.11% | 89.23% | 87.66% | 93.31% |
Operating Margin | -271.19% | -358.38% | -326.41% | -68.74% | -91.63% | -26.33% |
Pretax Margin | -295.20% | -374.78% | -341.82% | -69.54% | -95.45% | -26.43% |
Profit Margin | -295.47% | -374.96% | -342.45% | -70.89% | -97.33% | -26.47% |
FCF Margin | -286.97% | -374.44% | -218.08% | -103.88% | -60.17% | -78.19% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Oct '26 Oct 26, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Forward PE | - | 137.38 | 137.38 | 137.38 | 137.38 | 137.38 |
PS Ratio | 11.16 | 11.77 | 9.01 | 5.51 | 5.33 | 7.27 |